|
|||||
Company |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount |
||
Aastrom Biosciences Inc. |
Convertible preferred stock and warrants |
3,000 preferred shares; warrants for 0.3M shares of common stock |
3 |
||
Abgenix Inc. |
Private placement of common stock |
1.8S |
75 |
||
Access Pharmaceuticals Inc. |
Private placement of common stock |
1.5S |
3 |
||
Advanced Viral Research Corp. |
Private placement of convertible debentures and warrants |
1W |
$2.3E |
||
Affymetrix Inc. |
Private placement of common stock |
1S |
32.5 |
||
Affymetrix Inc. |
Private placement of convertible subordinated notes |
- |
150 |
||
Amarillo Biosciences Inc. |
Conversion of debt into equity |
0.95S |
2.8 |
||
Amylin Pharmaceuticals Inc. |
Private placement of preferred stock |
0.125S |
15 |
||
Amylin Pharmaceuticals Inc. |
Sale of division |
- |
2.6 |
||
Amylin Pharmaceuticals Inc. |
Private placement of common stock |
3.7S |
18.5 |
||
Aphton Corp. |
Private placement of common stock |
0.8S |
11.2 |
||
Aquila Biopharmaceuticals Inc. |
Direct limited placement of newly issued shares of common stock |
0.7S |
1.5 |
||
Aradigm Corp. |
PIPE |
2.4S |
25.5 |
||
Aronex Pharmaceuticals Inc. |
Institutional offering of registered stock |
6.0S |
13.1 |
||
Avanir Pharmaceuticals |
Equity line |
- |
10 |
||
Avant Immunotherapeutics Inc. |
Private placement of common stock |
5.5S |
10.5 |
||
AVAX Technologies Inc. |
Private placement of shares and warrants |
0.1S, 0.62W |
10.1 |
||
AVI Biopharma Inc. |
Private placement of common stock |
ND |
6.5 |
||
Avigen Inc. |
Private placement |
ND |
5.8 |
||
Avigen Inc. |
Private placement of common stock and warrants |
2.2S; 0.44W |
13.1 |
||
Avigen Inc. |
Private placement of common stock and warrants |
ND |
40 |
||
Aviron |
Private placement of common stock |
0.4S |
$6E |
||
Aviron |
Private placement of common stock |
0.26S |
5.3 |
||
Axonyx Inc. |
Private placement of common stock and warrants |
170 units of 0.004S and 0.002W |
4.25 |
||
BioChem Pharma Inc. |
Sale of diagnostics subsidiary |
- |
ND |
||
Bio-Technology General Corp. |
Exercise of warrants |
3.1W |
17 |
||
BioTime Inc. |
Rights offer |
0.75S |
7.3 |
||
BioTransplant Inc. |
Private placement of common stock |
1.7S |
7.7 |
||
Boston Biomedica Inc. |
Private placement of common stock purchase warrants |
0.5W |
2.2 |
||
Boston Life Sciences Inc. |
Private placements |
2.19S |
8.5 |
||
Boston Life Sciences Inc. |
Private placement of convertible debentures |
- |
8 |
||
Calypte Biomedical Corp. |
Private placement of common stock |
3.4S |
$7E |
||
Celgene Corp. |
Convertible notes |
- |
15 |
||
Celgene Corp. |
Convertible notes |
- |
15 |
||
Cellegy Pharmaceuticals Inc. |
Private placement of common stock |
1.6S |
10.1 |
||
Cellex Biosciences Inc. |
Debtor-inpossession financing |
- |
0.9 |
||
Celsion Corp. |
Exercise of warrants |
- |
1 |
||
Cell Pathways Inc. |
Private placement of common stock |
1.5S |
14 |
||
Cell Therapeutics Inc. |
Private placement of convertible preferred stock |
- |
10 |
||
Cel-Sci Corp. |
Private placement of common stock |
ND |
2.5 |
||
Cephalon Inc. |
Revenuesharing notes |
- |
30 |
||
Cephalon Inc. |
Private placement of convertible, exchangeable preferred stock |
2S |
100 |
||
Cephalon Inc. |
Private placement of convertible, exchangeable preferred stock |
0.5S |
25 |
||
Cerus Corp. |
Private placement of common stock |
1S |
25 |
||
Cocensys Inc. |
Sale of stake in Cytovia Inc. |
- |
3.3 |
||
CollaGenex Pharmaceuticals Inc. |
Private placement of convertible preferred stock |
- |
20 |
||
Collateral Therapeutics Inc. |
Private placement of common stock |
2.2S |
33.9 |
||
Corixa Corp. |
Equity-based credit line |
|
50 |
||
Corvas International Inc. |
Private placement of common stock and convertible note |
1.3S |
9.75 |
||
Corvas International Inc. |
Private placement of common stock and securities |
0.7S |
5.25 |
||
Cubist Pharmaceuticals Inc. |
Private placement of common stock |
2.5S |
18.8 |
||
CuraGen Corp. |
Private placement of common stock |
1.5S |
15 |
||
Cypress Bioscience Inc. |
Exercise of publicly traded warrants |
2.8W |
5.2 |
||
Cytel Corp. |
Sale of Glytec business unit |
- |
5 |
||
Cytogen Corp. |
Private placement |
6S |
4.5 |
||
Cytogen Corp. |
Private placement of common stock |
3.1S |
5 |
||
Diatide Inc. |
Private placement |
0.83S |
6 |
||
Digene Corp. |
Private placement of common stock |
1.5S |
19.5 |
||
Digene Corp. |
Private placement of common stock |
1.5S |
19.5 |
||
Discovery Laboratories Inc. |
Private placement of common stock and warrants |
- |
2.45 |
||
DNAP Holding Corp. |
Loan |
- |
30 |
||
Dusa Pharmaceuticals Inc. |
Private placement |
1.5S |
7.5 |
||
Endorex Corp. |
Line of credit |
- |
0.8 |
||
Endovasc Ltd. |
Debt financing |
- |
0.5 |
||
EntreMed Inc. |
Private placement of common stock and two series of warrants |
- |
25 |
||
Epoch Pharmaceuticals Inc. |
Private placement of stock |
1.25S |
3 |
||
Gensia Sicor Inc. |
Private placement of units |
8.70U |
35 |
||
Genta Inc. |
Sale of subsidiary |
- |
6.2 |
||
Genta Inc. |
Private placement of units |
- |
11.4 |
||
Genzyme Transgenics Corp. |
Private placement of common stock |
ND |
5.4 |
||
Geron Corp. |
Sale of convertible debentures and warrants |
- |
12.5 |
||
Guilford Pharmaceuticals Inc. |
Private placement of common stock |
3.4S |
45 |
||
Helix BioMedix Inc. |
Private equity financing |
ND |
2 |
||
Heska Corp. |
Private placement of common stock |
6.5S |
13.3 |
||
Hollis-Eden Pharmaceuticals Inc. |
Private placement |
0.72S |
13 |
||
Hollis-Eden Pharmaceuticals Inc. |
Private placement |
0.65S |
12 |
||
Human Genome Sciences Inc. |
Convertible notes |
- |
100 |
||
Human Genome Sciences Inc. |
Convertible notes |
- |
25 |
||
Human Genome Sciences |
Private placement of notes |
- |
200 |
||
Hyal Pharmaceutical Corp. |
Sale of ownership in subsidiary |
- |
1.3 |
||
ID Biomedical Corp. |
Private placement of warrants |
2W |
C$5.5 (US$3.76) |
||
Idec Pharmaceuticals Corp. |
Liquid yield option notes |
- |
115 |
||
IGEN International Inc. |
Debt financing |
- |
30 |
||
Ilex Oncology Inc. |
Private placement of common stock |
2.4S |
20 |
||
The Immune Response Corp. |
Private placement of common stock |
0.6S |
3 |
||
The Immune Response Corp. |
Private placement of common stock |
0.8S |
3.1 |
||
Immunomedics Inc. |
Private placement of common stock |
2.5S |
7.5 |
||
Inex Pharmaceuticals Corp. |
Private placement of warrants |
5.5W (US$7.5)* |
C$11M |
||
Inex Pharmaceuticals Corp. |
Special warrant financing |
6W |
C$12 (US$8) |
||
Inflazyme Pharmaceuticals Ltd. |
Release of special warrants funds |
- |
C$15.5 (US$10.5) |
||
Inhale Therapeutic Systems Inc. |
Private placement of convertible subordinated debentures |
- |
100 |
||
InKine Pharmaceutical Inc. |
Private placement of common stock and warrant |
2.3S and 1W |
3 |
||
International Isotopes Inc. |
Private placement of units and placement of convertible preferred stock |
1.04U (each unit consists of 1S and and 1W) |
19.5 ($9.5 from units, $10 from preferred convertibles) |
||
LeukoSite Inc. |
Private placement of common stock |
1.5S |
14.4 |
||
Ligand Pharmaceuticals Inc. |
Exercise of warrants |
2.27S |
12.5 |
||
Ligand Pharmaceuticals Inc. |
Exchange of warrants |
2.3W |
13.9 |
||
LJL BioSystems Inc. |
Private placement |
2.0S |
7 |
||
Lorus Therapeutics Inc. |
Private placement |
5.33W |
1.1 |
||
Lorus Therapeutics Inc. |
Private placement of warrants |
30.3W |
C$10 (US$6.83) |
||
Martek Biosciences Corp. |
Private placement of shares and warrants |
1.5S; warrants for 0.45S |
13.5 |
||
Matritech Inc. |
Private placement |
3.1S |
4 |
||
Matritech Inc. |
Private placement of units |
0.9 units of 2S and 1W |
3.6 |
||
Maxim Pharmaceuticals Inc. |
Private placement of convertible preferred stock |
- |
20 |
||
Maxim Pharmaceuticals Inc. |
Private placement of convertible preferred stock |
- |
20.6 |
||
Micrologix Biotech Inc. |
Special units financing |
7.7U |
C$15 (US$10.1) |
||
Neoprobe Corp. |
Private placement of convertible preferred stock |
0.03S |
3 |
||
Neose Technologies Inc. |
Private placement of common stock |
1.5S |
14.25 |
||
NeoTherapeutics Inc. |
Private placement |
1.53S |
4 |
||
NeoTherapeutics Inc. |
Private placement of common stock and warrants |
0.4S, warrants for 0.08S |
4 |
||
NeoTherapeutics Inc. |
Private placement of common stock |
0.8S |
10 |
||
Neurobiological Technologies Inc. |
Private financing |
ND |
1.1 |
||
Neurobiological Technologies Inc. |
Loan agreement |
- |
1.5 |
||
Neurobiological Technologies Inc. |
Private placement of securities |
Units of 5S stock and 1W |
4.2 |
||
Neurocrine Biosciences Inc. |
Private placement of common stock |
2.3S |
42 |
||
Nexell Therapeutics Inc. |
Private placement of convertible preferred stock |
0.063S |
63 |
||
Nymox Pharmaceutical Corp. |
Private placement of common stock |
ND |
12 |
||
Oncolytics Biotech Inc. (a subsidiary of Synsorb Biotech Inc.) |
Private placement of special warrants |
1.5W |
C$0.9 (US$0.6) |
||
Ophidian Pharmaceuticals Inc. |
Senior note financing |
- |
2 |
||
Organogenesis Inc. |
Private placement of convertible debentures |
- |
20 |
||
Orphan Medical Inc. |
Private placement of convertible stock and debt financing |
- |
5 |
||
Ortec International Inc. |
Private placement of common stock |
1.6S |
9 |
||
Oxford BioMedica plc |
Rights issue |
23.7S |
5.8 |
||
Oxford Glycosciences plc |
Sale of biochemicals business |
- |
2.1 |
||
Palatin Technologies Inc. |
Private placement |
ND |
3.8 |
||
Paracelsian Inc. |
Private placement |
ND |
0.4 |
||
Peptide Therapeutics Group plc |
Rights offering |
29.3S |
37.5 |
||
Phage Therapeutics International Inc. |
Private placement |
3.0S |
0.2 |
||
Phage Therapeutics International Inc. |
Private placement of common stock |
0.75MS |
0.15 |
||
Precision Biochemicals Inc. (a subsidiary of IGT Pharma Inc.) |
Private placement of equity |
- |
C$0.5 (US$0.34) |
||
Procyon Biopharma Inc. |
Private placement of common stock |
12S |
2 |
||
Protein Polymer Technologies Inc. |
Private placement of convertible preferred stock |
0.035S |
1.8 |
||
Repligen Corp. |
Private placement of common stock |
3.6S |
9 |
||
RiboGene Inc. |
Loan |
- |
5 |
||
SangStat Medical Corp. |
Convertible debt financing |
- |
10 |
||
SciClone Pharmaceuticals |
Private placement of shares and warrants |
1.37U (each consisting of one share and one warrant to purchase one share) |
2 |
||
SciClone Pharmaceuticals |
Private placement of shares and warrants |
2.5U (each unit consists of 1S and 1W) |
4 |
||
Sugen Inc. |
Private placement of convertible notes |
- |
28 |
||
SuperGen Inc. |
Private placement |
ND |
16.6 |
||
Theratechnologies |
Private placement of units |
0.6U |
C$6 (US$4.1) |
||
Theratechnologies |
Exercise of warrants |
0.5W |
2.6 |
||
Titan Pharmaceuticals Inc. |
Private placement |
2.25S |
6.2 |
||
Transkaryotic Therapies Inc. |
Private investment in a public entity (PIPE) |
3.3S |
132 |
||
United Therapeutics Corp. |
Private placement of common stock |
2.5S |
80 |
||
U.S. Bioscience Inc. |
Private placement |
2.69S |
20 |
||
VaxGen Inc. |
Private placement of common stock |
ND |
25 |
||
Vion Pharmaceuticals Inc. |
Direct private placement |
0.89S |
4 |
||
Viragen Inc. |
Private placement |
ND |
9 |
||
Viragen Inc. |
Private placement |
3S and additional convertible notes |
3 |
||
ViroPharma Inc. |
Private placement of preferred shares |
2.3S |
14.3 |
||
Visible Genetics Inc. |
Equity investment in exchange for preferred convertible stock and warrants |
1.1W |
C$30 (US$20) |
||
Xenova Group plc |
Private placement of shares, exercising of warrants |
2.2S; 5W |
6.1 (US$9.9) |
||
Xenova Group plc |
Net cash payment for sale of assets |
- |
0.24 (US$0.38) |
||
Xoma Ltd. |
Private placement |
2.0S |
12 |
||
Xoma Ltd. |
Private placement of common stock |
3S |
17.4 |
|
||||||
Company |
Location |
Date |
Amount Raised (M) |
Round |
||
Aclara BioSciences Inc. |
Hayward, Calif. |
2/23 |
15 |
N/A |
||
Aclara BioSciences Inc. |
Hayward, Calif. |
3/23 |
3 |
Private placement |
||
Adolor Corp. |
Malvern, Pa. |
3/17 |
8.5 |
Private placement |
||
Ambryx Inc. |
San Diego |
10/25 |
12.3 |
First |
||
Antigenics LLC |
New York |
1/11 |
28 |
Fourth |
||
Arcaris Inc. |
Salt Lake City |
5/10 |
8 |
Second |
||
Arena Pharmaceuticals Inc. |
San Diego |
2/22 |
17 |
Fourth |
||
Argonex Inc. |
Charlottesville, Va. |
12/7 |
9.6 |
Second |
||
Array Biopharma Inc. |
Boulder, Colo. |
12/7 |
8 |
Second |
||
AtheroGenics Inc. |
Alpharetta, Ga. |
5/17 |
15.9 |
N/A |
||
AtheroGenics Inc. |
Alpharetta, Ga. |
9/15 |
8 |
Third |
||
Atugen Biotechnology GmbH |
Berlin |
1/29 |
13 |
Seed |
||
BioImage A/S |
Copenhagen, Denmark |
4/28 |
17 |
First |
||
BioMarin Pharmaceutical Inc. |
Novato, Calif. |
4/14 |
26 |
Second |
||
Biostar Inc. |
Saskatoon, Saskatchewan |
2/18 |
2.1 |
Mezzanine |
||
BioStratum Inc. |
Research Triangle Park, N.C. |
4/1 |
6 |
First |
||
Biosyn Inc. |
Philadelphia |
7/1 |
8.5 |
First |
||
Calydon Inc. |
Sunnyvale, Calif. |
6/10 |
10.1 |
Mezzanine |
||
Cambridge Genetics Ltd. |
Cambridge, England |
N/A |
#4 (US$6.4) |
First |
||
Ceptyr Inc. |
Bothell, Wash. |
8/2 |
11.5 |
Third |
||
Circe Biomedical Inc. |
Lexington, Mass. |
4/6 |
16.4 |
First |
||
Coelacanth Corp. |
East Windsor, N.J. |
5/5 |
9 |
Third |
||
Combimatrix Corp. |
Burlingame, Calif. |
8/10 |
4 |
N/A |
||
Conjuchem Inc. |
Montreal |
8/9 |
C$12.7 (US$8.5) |
Second |
||
CpG ImmunoPharmaceuticals |
Wellesley, Mass. |
8/3 |
12.9 |
Second |
||
Cyclacel Ltd. |
Dundee, UK |
5/10 |
#5.3 (US$8.5) |
Second |
||
Cyclacel Ltd. |
Dundee, Scotland |
8/16 |
#4 (US$6.5) |
Third |
||
Cytochroma Inc. |
Kingston, Ontario |
N/D |
C$2.1 (US$1.4) |
First |
||
Cytokinetics Inc. |
South San Francisco |
9/9 |
20 |
Second |
||
Dendreon Corp. |
Seattle |
10/22 |
10 |
Round N/D |
||
Durect Corp. |
Cupertino, Calif. |
8/2 |
20 |
Second |
||
Elitra Pharmaceuticals Inc. |
San Diego |
7/20 |
16 |
Second |
||
Encelle Inc. |
Raleigh, N.C. |
4/26 |
5 |
Mezzanine |
||
eNOS Pharmaceuticals Inc. |
Cambridge, Mass. |
8/25 |
ND |
First |
||
EntoMed |
Strasbourg, France |
3/22 |
3.6 |
First |
||
Eos Biotechnology Inc. |
South San Francisco |
9/27 |
27 |
Round N/D |
||
Epic Therapeutics Inc. |
Norwood, Mass. |
5/10 |
12.5 |
Funding Round N/D |
||
Epicyte Pharmaceutical Inc. |
San Diego |
1/25 |
4.5 |
Second |
||
Epigenomics GmbH |
Berlin |
N/A |
DM14.5 (US$7.7) |
Seed |
||
FibroGen Europe Ltd. |
Oulu, Finland |
8/2 |
15.3 |
First and Second |
||
Gemini Holdings plc |
Cambridge, England |
N/A |
#9.2 (US$14.9) |
Third |
||
Genmab |
Denmark |
3/3 |
5.5 |
Seed |
||
Genomica Corp. |
Boulder, Colo. |
3/1 |
13.6 |
Second |
||
IBC Pharmaceuticals LLC |
Morris Plains, N.J. |
3/12 |
2.45 |
N/A |
||
ICAgen Inc. |
Research Triangle Park, N.C. |
11/30 |
19 |
Round N/D |
||
Idun Pharmaceuticals |
La Jolla, Calif. |
9/14 |
7.4 |
Mezzanine |
||
Immunicon Corp. |
Huntingdon Valley, Pa. |
3/24 |
10.7 |
Mezzanine |
||
Inpharmatica Ltd. |
London |
3/9 |
4.8 |
Second |
||
Inspire Pharmaceuticals |
Durham, N.C. |
11/2 |
12.4 |
Round N/D |
||
InterMune Pharmaceuticals Inc. |
Palo Alto, Calif. |
4/30 |
6 |
First |
||
InterMune Pharmaceuticals Inc. |
Palo Alto, Calif. |
8/20 |
1.5 |
First |
||
IntraBiotics Pharmaceuticals Inc. |
Mountain View, Calif. |
2/1 |
23 |
N/A |
||
IntraBiotics Pharmaceuticals Inc. |
Mountain View, Calif. |
11/17 |
25 |
Mezzanine |
||
IntraTherapeutics Inc. |
St. Paul, Minn. |
10/8 |
7.5 |
Mezzanine |
||
IsoTis BV |
Bilthoven, the Netherlands |
6/21 |
Euro18.2 (US$18.8) |
Round N/D |
||
Kimeragen Inc. |
Newtown, Pa. |
5/18 |
7.5 |
Round N/D |
||
Kinetek Pharmaceuticals Inc. |
Vancouver, British Columbia |
8/18 |
C$7.9 (US$5.3) |
First |
||
Kinetix Pharmaceuticals Inc. |
Medford, Mass. |
4/15 |
8.8 |
Second |
||
KuDOS Pharmaceuticals Ltd. |
Cambridge, England |
N/A |
#5 (US$8) |
First |
||
Link Technology Inc. |
Research Triangle Park, N.C. |
9/23 |
0.75 |
Seed |
||
Maxygen Inc. |
Redwood City, Calif. |
7/14 |
20 |
Fourth |
||
Medinox Inc. |
San Diego |
6/22 |
7.4 |
Mezzanine |
||
Microscience Ltd. |
London |
6/8 |
#9 (US$14.2) |
Round N/D |
||
Morphochem AG |
Munich, Germany |
9/1 |
DM28 US$15.1 |
Second |
||
Myogen Inc. |
Boulder, Colo. |
12/15 |
18 |
Third |
||
Novirio Pharmaceuticals Ltd. |
Cambridge, Mass. |
11/5 |
12.5 |
Round N/D |
||
Orchid Biocomputer Inc. |
Princeton, N.J. |
3/10 |
16 |
N/A |
||
OriGenix Technologies Inc. |
Montreal |
1/28 |
4 |
Seed |
||
Origenix Technologies Inc. |
Montreal |
12/13 |
2 |
Round N/D |
||
Pangea Systems Inc. |
Oakland, Calif. |
2/22 |
4 |
Second |
||
Pentose Pharmaceuticals Inc. |
Cambridge, Mass. |
1/6 |
7 |
Second |
||
Pepgen Corp. |
Alameda, Calif. |
10/6 |
3.8 |
Round N/D |
||
Pharmadigm Inc. |
Salt Lake City |
4/19 |
8.6 |
Third |
||
Quorex Pharmaceuticals Inc. |
Carlsbad, Calif. |
12/6 |
1.1 |
First |
||
Regen Biologics Inc. |
Redwood City, Calif. |
1/25 |
6 |
N/A |
||
Reprogenesis Inc. |
Cambridge, Mass. |
9/15 |
10.5 |
Second |
||
RxKinetix Inc. |
Louisville, Colo. |
9/1 |
4.1 |
First and Second |
||
Salus Therapeutics Inc. |
Salt Lake City |
11/17 |
1 |
Round N/D |
||
Sangamo BioSciences Inc. |
Point Richmond, Calif. |
10/18 |
7.5 |
Third |
||
Santarus Inc. |
San Diego |
8/17 |
4.8 |
First |
||
Sequenom |
San Diego |
4/19 |
37 |
Third |
||
Structural GenomiX |
San Diego |
12/15 |
7.5 |
First |
||
Sunesis Pharmaceuticals Inc. |
Redwood City, Calif. |
12/6 |
25.2 |
Second |
||
Symyx Technologies |
Santa Clara, Calif. |
1/12 |
23 |
N/A |
||
t. Breeders Inc. |
Worcester, Mass. |
7/7 |
5.95 |
Round N/D |
||
Tanox Inc. |
Houston |
12/13 |
23.7 |
Round N/D |
||
TerraGen Discovery Inc. |
Vancouver, British Columbia |
4/19 |
C$8 (US$5.5) |
Second |
||
Therion Biologics Corp. |
Cambridge, Mass. |
6/28 |
10.5 |
Round N/D |
||
Third Wave Technologies Inc. |
Madison, Wis. |
7/27 |
19.5 |
Mezzanine |
||
Triad Biotechnology Inc. |
Rancho Santa Fe, Calif. |
7/2 |
12 |
Seed |
||
UroGenesys Inc. |
Santa Monica, Calif. |
10/11 |
11.3 |
Second |
||
Variagenics Inc. |
Cambridge, Mass. |
8/2 |
19 |
Second |
||
Vascular Genetics Inc. |
Durham, N.C. |
3/29 |
ND |
First |
||
Versicor Inc. |
Fremont, Calif. |
11/3 |
40 |
Round N/D |
||
Versicor Inc. |
Fremont, Calif. |
12/9 |
0.5 |
N/A |
||
VitaGen Inc. |
La Jolla, Calif. |
6/24 |
10.5 |
Mezzanine |
||
Xencor Inc. |
Pasadena, Calif. |
6/14 |
12.3 |
Second |
||
Zarix Ltd. |
Hamilton, Bermuda |
1/25 |
5.5 |
First |
Back to Top